American Association of Clinical Endocrinologists (AACE) Responds to Reports Associating Testosterone Replacement Therapy with Increased Cardiovascular Risk

JACKSONVILLE, Fla.–(BUSINESS WIRE)–Citing the lack of compelling evidence connecting testosterone
replacement therapy (TRT) with cardiovascular events such as heart
attack and stroke, physicians representing the American
Association of Clinical Endocrinologists (AACE)
today issued a
position statement questioning claims that testosterone replacement
therapy (TRT) increases the risk of cardiovascular disease among users.

While several recently published studies support the association of low
testosterone concentrations with cardiovascular problems, especially in
older men, the AACE position statement notes that low testosterone is
often a marker of cardiovascular illness, not a causal factor.

Additionally, the AACE position statement highlights the significant
benefits of TRT in men with cardiovascular risk factors, including a
decrease in fat mass, an increase in muscle mass, decreased insulin
resistance and a reversal of metabolic syndrome in some patients.
However, an assessment of any TRT benefits, and potential AACE support
for its use, needs to come from patients with documented hypogonadism
(i.e., low testosterone), notes AACE president Dr.
George Grunberger

The position statement, prepared by AACE’s Reproductive Endocrinology
Scientific Committee, called for large-scale studies focusing on
controlled trials to determine the impact of TRT on cardiovascular
disease risk. In the interim, AACE recommends TRT clinical decisions be
guided by individual patients’ signs and symptoms and testosterone
concentrations rather than the underlying cause of low testosterone such
as aging.

The position statement is published in Volume 21, Issue 9, September
2015 edition of AACE’s peer-reviewed medical journal Endocrine
and can be viewed here:

About the American Association of Clinical
Endocrinologists (AACE)

The American Association of Clinical Endocrinologists (AACE) represents
more than 6,000 endocrinologists in the United States and abroad. AACE
is the largest association of clinical endocrinologists in the world.
The majority of AACE members are certified in diabetes, endocrinology
and metabolism and concentrate on the treatment of patients with
endocrine and metabolic disorders including diabetes, thyroid disorders,
osteoporosis, growth hormone deficiency, cholesterol disorders,
hypertension and obesity. Visit our website at

About the Journal

, the official journal of the American College of
Endocrinology (ACE) and the American Association of Clinical
Endocrinologists (AACE), is a peer-reviewed journal published twelve
times a year. The Journal publishes the latest information in the
treatment of diabetes, thyroid disease, obesity, growth hormone
deficiency, sexual dysfunction and osteoporosis, and contains original
articles, case reports, review articles, commentaries, editorials,
visual vignettes, as well as classified and display advertising. Special
issues of Endocrine Practice also include AACE clinical practice
guidelines and other AACE/ACE white papers. Complete content is
available on the Endocrine Practice website at


AACE Public & Media Relations
Glenn Sebold, 904-404-4122